| PharmVar GeneFocus: CYP2D6 C Nofziger, AJ Turner, K Sangkuhl, M Whirl‐Carrillo, JAG Agúndez, ... Clinical Pharmacology & Therapeutics 107 (1), 154-170, 2020 | 247 | 2020 |
| Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ... Clinical Pharmacology & Therapeutics 99 (2), 172-185, 2016 | 218 | 2016 |
| Recommendations for clinical CYP2C19 genotyping allele selection: a report of the Association for Molecular Pathology VM Pratt, AL Del Tredici, H Hachad, Y Ji, LV Kalman, SA Scott, KE Weck The Journal of Molecular Diagnostics 20 (3), 269-276, 2018 | 212 | 2018 |
| New antiepileptic drugs: review on drug interactions H Hachad, I Ragueneau-Majlessi, RH Levy Therapeutic drug monitoring 24 (1), 91-103, 2002 | 201 | 2002 |
| γ-glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system R Drozdz, C Parmentier, H Hachad, P Leroy, G ́erard Siest, M Wellman Free Radical Biology and Medicine 25 (7), 786-792, 1998 | 199 | 1998 |
| Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists … VM Pratt, LH Cavallari, AL Del Tredici, A Gaedigk, H Hachad, Y Ji, ... The Journal of Molecular Diagnostics 23 (9), 1047-1064, 2021 | 139 | 2021 |
| Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American Pathologists VM Pratt, LH Cavallari, AL Del Tredici, H Hachad, Y Ji, AM Moyer, ... The Journal of Molecular Diagnostics 21 (5), 746-755, 2019 | 133 | 2019 |
| Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad … GL Birbeck, JA French, E Perucca, DM Simpson, H Fraimow, JM George, ... Neurology 78 (2), 139-145, 2012 | 113 | 2012 |
| Are circulating metabolites important in drug–drug interactions?: quantitative analysis of risk prediction and inhibitory potency CK Yeung, Y Fujioka, H Hachad, RH Levy, N Isoherranen Clinical Pharmacology & Therapeutics 89 (1), 105-113, 2011 | 80 | 2011 |
| Qualitative analysis of the role of metabolites in inhibitory drug− drug interactions: literature evaluation based on the metabolism and transport drug interaction database N Isoherranen, H Hachad, CK Yeung, RH Levy Chemical research in toxicology 22 (2), 294-298, 2009 | 72 | 2009 |
| Antiepileptic drug selection for people with HIV/AIDS: evidence‐based guidelines from the ILAE and AAN GL Birbeck, JA French, E Perucca, DM Simpson, H Fraimow, JM George, ... Epilepsia 53 (1), 207-214, 2012 | 68 | 2012 |
| A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database H Hachad, I Ragueneau-Majlessi, RH Levy Human genomics 5, 1-12, 2010 | 63 | 2010 |
| Recommendations for clinical warfarin genotyping allele selection: a report of the Association for Molecular Pathology and the College of American Pathologists VM Pratt, LH Cavallari, AL Del Tredici, H Hachad, Y Ji, LV Kalman, RC Ly, ... The Journal of Molecular Diagnostics 22 (7), 847-859, 2020 | 60 | 2020 |
| Valproic acid: chemistry, biotransformation and pharmacokinetics RH Levy, DD Shen, FS Abbott, KW Riggs, H Hachad Antiepileptic drugs, 780-800, 2002 | 56 | 2002 |
| TPMT and NUDT15 genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation consortium … VM Pratt, LH Cavallari, ML Fulmer, A Gaedigk, H Hachad, Y Ji, LV Kalman, ... The Journal of Molecular Diagnostics 24 (10), 1051-1063, 2022 | 46 | 2022 |
| Importance of multi-p450 inhibition in drug–drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data N Isoherranen, JD Lutz, SP Chung, H Hachad, RH Levy, ... Chemical research in toxicology 25 (11), 2285-2300, 2012 | 42 | 2012 |
| CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the association for molecular Pathology, clinical pharmacogenetics implementation Consortium … VM Pratt, LH Cavallari, ML Fulmer, A Gaedigk, H Hachad, Y Ji, LV Kalman, ... The Journal of Molecular Diagnostics 25 (9), 619-629, 2023 | 38 | 2023 |
| Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database RH Levy, H Hachad, C Yao, I Ragueneau-Majlessi Current drug metabolism 4 (5), 371-380, 2003 | 22 | 2003 |
| PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting AJ Turner, C Nofziger, BE Ramey, RC Ly, CA Bousman, JAG Agúndez, ... Clinical Pharmacology & Therapeutics 114 (6), 1220-1237, 2023 | 21 | 2023 |
| Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis I Ragueneau-Majlessi, X Boulenc, C Rauch, H Hachad, RH Levy Current drug metabolism 8 (8), 810-814, 2007 | 20 | 2007 |
Michelle Whirl-CarrilloStanford UniversityEmail verificata su stanford.edu
